US Senator Charles Grassley, in a letter to the head of the federal Securities and Exchange Commission Thursday, said he is concerned about a recent dramatic jump in Vertex Pharmaceuticals Inc.’s stock price that followed overstated test data for a drug it’s developing.
BostonGlobe.comSubscriber Log-in
Contact us for help
- Phone
888-MY-GLOBE
Monday-Friday 6:00 a.m.- 5:00 p.m.
Saturday, Sunday and Holidays 7:30 a.m.- 12:00 noon
- Chat
Monday-Sunday 8:00 a.m.- 5:00 p.m.
Comments